98%
921
2 minutes
20
Bacterial keratitis is a prevalent, and severe corneal illness resulting from bacterial pathogens. Failure to administer a timely and suitable therapy may lead to corneal opacity, ulceration, significant vision impairment, or potential blindness. Current clinical interventions for bacterial keratitis involve the administration of topical antimicrobial agents and systemic antibiotics. However, the misuse and overuse of antibiotics have led to the rapid emergence of antibiotic-resistant bacteria. Additionally, the restricted antibacterial spectrum and possible adverse effects of antibiotics have provided considerable obstacles to traditional therapies. This highlights the urgent need for novel and highly effective antimicrobial agents. Antimicrobial peptides (AMPs) are a class of naturally occurring or synthetically designed small molecules that have gained significant attention due to their unique antimicrobial mechanisms and low risk of resistance development. AMPs exhibit promising potential in treating bacterial keratitis through direct antibacterial mechanisms, such as inhibiting cell wall synthesis, disrupting cell membranes, and interfering with nucleic acid metabolism, as well as indirect mechanisms, including modulation of the host immune response. This review provides a comprehensive overview of the antibacterial mechanisms of AMPs and their advancements in the treatment of bacterial keratitis. It emphasizes the role of various modification strategies and artificial-intelligence-assisted design in enhancing the antibacterial efficacy, stability, and biocompatibility of AMPs. Furthermore, this review discusses the latest progress in combining AMPs with delivery systems for improved therapeutic outcomes. Finally, the review highlights the current challenges and future perspectives of AMPs in bacterial keratitis treatment, providing valuable insights for developing novel AMPs with high antibacterial efficacy, stability, and safety for bacterial keratitis therapies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.bioconjchem.4c00594 | DOI Listing |
NPJ Antimicrob Resist
September 2025
Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Graduate Medical School, Singapore, Singapore.
Pseudomonas aeruginosa (PA) represents a major cause of antimicrobial resistance-related morbidity and mortality. The recent emergence of highly fatal infections, caused by carbapenem-resistant PA, has called for novel antimicrobial therapies and strategies. In this study, we highlight the therapeutic potential of ε-poly-L-lysine (εPL), an antimicrobial polymer for treating extensively-and pan-drug-resistant-PA.
View Article and Find Full Text PDFCornea
September 2025
Department of Ophthalmology, University of California Los Angeles, Los Angeles, CA.
Purpose: To evaluate visual outcomes after bacterial keratitis (BK) and identify predictive factors for poor prognosis at a tertiary referral center in Southern California.
Methods: This is a cross-sectional retrospective review of patients' medical records with culture-positive BK at University of California Los Angeles from January 1, 2014, to December 31, 2019. Main outcome measure was change in best-corrected visual acuity (BCVA) at 12 weeks posttreatment.
Wellcome Open Res
January 2025
London School of Hygiene & Tropical Medicine, International Centre for Eye Health, London, UK.
Purpose: To determine the knowledge, attitude, and practice of pharmacy attendants in the management of microbial keratitis.
Methods: This mixed-methods study was conducted in selected pharmacies and drug shops located in Mbarara City between March and May 2022. We administered questionnaires assessing the knowledge, attitudes, and practices (KAP) related to microbial keratitis (MK) to 140 pharmacy attendants (PAs) in the drug shops and pharmacies.
Eur J Med Chem
December 2025
Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences. Lanzhou University, West Donggang Road 199, Lanzhou, 730000, PR China. Electronic address:
Lugdunin, a newly discovered antibiotic with a unique structure, emerged during a decade-long antibiotic discovery void and is considered a promising lead for combating drug-resistant bacteria. However, its narrow spectrum targeting only Gram-positive bacteria and its structural limitations have hindered its development and clinical application. Herein, inspired by our previous combinatorial modification strategies for lugdunin, we designed and synthesized a series of multi-cationic lugdunin derivatives using a biphenylmethyl modification on the tryptophan indole structure combined with multi-cationic amino acid mutations, aiming to expand its antimicrobial spectrum.
View Article and Find Full Text PDF